Amarin Corporation PLC Plummets After Fish Oil Pill Fails to Win Backing; Stock Down -61.12% at Market Close (October 17, 2013)

Published: Oct 18, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Amarin Corp. lost more than half its value in early trading after the company failed to win the backing of U.S. advisers to expand use of its fish-oil pill Vascepa for those with high levels of fat in their blood. Amarin’s American depositary receipts fell 62 percent to $1.97 at 7:52 a.m. New York time. The company had already dropped 54 percent in the 12 months through Oct. 15. Trading was halted yesterday during the advisory panel meeting.

Help employers find you! Check out all the jobs and post your resume.

Back to news